Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2504 studies found for:    vaccines | Child
Show Display Options
Rank Status Study
1 Completed School Influenza Vaccine vs Standard of Care With Nested Trial of 2 Parent Notification Intensities
Conditions: Immunizations;   Vaccination;   Influenza;   School Health
Interventions: Behavioral: School based flu vaccine: Low intensity;   Behavioral: School based flu vaccine: High intensity
2 Completed
Has Results
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
Condition: Meningitis, Meningococcal
Interventions: Biological: Meningococcal ACWY Conjugate Vaccine;   Biological: DTaP-IPV-HBV;   Biological: Hib;   Biological: Rotavirus;   Biological: Pneumococcal 7-valent Conjugate Vaccine;   Biological: HAV;   Biological: MMR-V;   Biological: DTaP
3 Recruiting Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study
Conditions: Intussusception;   Rotavirus Infections
Interventions: Drug: Rotarix®,;   Drug: Rotarix®, with other routine vaccines;   Drug: RotaTeq®,;   Drug: RotaTeq®, with other routine vaccines
4 Active, not recruiting Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
Conditions: Meningitis;   Meningococcal Meningitis;   Meningococcal Infections
Interventions: Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine;   Biological: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
5 Completed
Has Results
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Conditions: Meningitis;   Meningococcal Infection
Interventions: Biological: MenACWY-CRM197;   Biological: DTaP (Diptheria, Tetanus, Pertussis) Vaccine;   Biological: Hib (Haemophilus influenza b) Vaccine;   Biological: IPV (Inactivated Polio Vaccine) Vaccine;   Biological: Pneumococcal conjugate Vaccine;   Biological: MMR (Measles, Mumps, and Rubella) Vaccine;   Biological: Varicella Vaccine;   Biological: Hepatitis A Virus
6 Completed
Has Results
Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents
Condition: Influenza
Interventions: Biological: Cell culture-derived influenza subunit vaccine (cTIV);   Biological: Egg derived influenza subunit vaccine (eTIV)
7 Active, not recruiting Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations
Condition: Influenza
Interventions: Biological: Fluzone Quadrivalent vaccine, 2016 2017 formulation, No Preservative;   Biological: Fluzone High Dose, vaccine, 2016 2017 formulation
8 Completed
Has Results
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Interventions: Biological: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine;   Biological: 2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
9 Completed Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
Conditions: Dengue;   Dengue Hemorrhagic Fever;   Yellow Fever
Interventions: Biological: Live, attenuated dengue serotype 1, 2, 3, and 4 virus;   Biological: Yellow fever vaccine;   Biological: Measles, mumps, and rubella vaccine;   Biological: Pneumococcal Conjugated Vaccine;   Biological: Hepatitis A Pediatric Vaccine;   Biological: Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine;   Biological: Yellow Fever Vaccine;   Biological: Placebo (NaCl)
10 Completed
Has Results
Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants
Condition: Prevention of Meningococcal Disease
Interventions: Biological: MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation);   Biological: MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation);   Biological: MenACWY PS (MenACWY-CRM, polysaccharide vaccine);   Biological: HBV (Hepatitis B vaccine);   Biological: Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197);   Biological: MMR (Measles, Mumps and Rubella vaccine);   Biological: DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine);   Biological: Menjugate (Men C conjugated vaccine)
11 Completed Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines
Conditions: Pneumococcal Disease;   Streptococcus Pneumoniae Vaccines
Interventions: Biological: Pneumococcal conjugate vaccine GSK1024850A;   Biological: Tritanrix-HepB;   Biological: Hiberix Hib vaccine;   Biological: Polio Sabin;   Biological: Poliorix;   Biological: Prevenar (Wyeth)
12 Completed Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents
Condition: Influenza
Interventions: Biological: Seasonal Influenza DNA vaccine;   Biological: TIV
13 Completed Safety of an Inactivated Enterovirus Type 71 Vaccines in Healthy Children
Conditions: Hand-foot-mouth Disease;   Infection; Viral, Enterovirus
Interventions: Biological: 100U inactivated Enterovirus Type 71 Vaccine;   Biological: 200U inactivated Enterovirus Type 71 Vaccine;   Biological: 400U inactivated Enterovirus Type 71 Vaccine;   Biological: Placebo
14 Completed
Has Results
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
Condition: Invasive Meningococcal Disease
Interventions: Biological: Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.;   Biological: Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.;   Biological: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.;   Biological: Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.
15 Completed
Has Results
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
Condition: Meningococcal Meningitis
Interventions: Biological: MenACWY-CRM conjugate vaccine;   Biological: Licensed comparator
16 Completed Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers
Conditions: Dengue;   Dengue Hemorrhagic Fever
Interventions: Biological: Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus;   Biological: DTaP IPV//Hib vaccine;   Biological: Placebo;   Biological: Measles, mumps, and rubella vaccine;   Biological: Pneumococcal vaccine
17 Completed Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine
Condition: Meningitis
Interventions: Biological: MCV-ACYW135 Vaccine Group;   Biological: MPV-ACYW135 Vaccine Group;   Biological: MPV-A Vaccine Group;   Biological: MCV-AC Vaccine Group;   Biological: Hib Vaccine Group
18 Completed Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine
Conditions: Rabies;   Rabies Virus
Interventions: Biological: Purified inactivated rabies vaccine, serum free;   Biological: Purified Vero Rabies Vaccine
19 Completed
Has Results
A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Interventions: Biological: rMenB + OMV NZ vaccine;   Biological: Meningococcal C oligosaccharide conjugated vaccine;   Biological: Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
20 Completed School Located Adolescent Vaccination Study
Condition: School Located Vaccine Program
Intervention: Behavioral: School Located Vaccine (SLV) Program

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years